Le Lézard
Classified in: Health, Business
Subjects: ERN, CCA

Nordic Nanovector ASA: Invitation to Third Quarter 2019 Results Presentation and Webcast


OSLO, Norway, Nov. 13, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the third quarter 2019 on Tuesday, 19 November 2019. A presentation by Nordic Nanovector's senior management team will take place at 8:30am CET at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: AKER

The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2019 from 7:00am CET the same day.

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com 

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com 

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--invitation-to-third-quarter-2019-results-presentation-and-webcast,c2960191

SOURCE Nordic Nanovector


These press releases may also interest you

at 05:00
Governments across the country have been denying Canadians access to vital information about the novel coronavirus and their responses to it, while failing to protect whistleblowers who could expose threats to public health ? whether they are in...

at 04:56
kneat.com, inc. ("Kneat"), announces that the Company will release its Financial Results for the quarter ended March 31, 2020 after TSX market close on Wednesday 27 May 2020. ...

at 04:35
The global tissue engineering market size is expected to reach USD 28.9 billion by 2027, expanding at a CAGR of 14.2%, according to a new report by Grand View Research, Inc. Allogenic tissue transplant method efficiently addresses challenges and...

at 04:23
Enzymatica and its partner STADA have extended its agreement for the cold spray ViruProtect® (ColdZyme) to cover another 19 countries in Europe. With the extended agreement STADA has provided order estimates of about SEK 20 million for 2020. The...

at 04:00
As governments in many countries are easing lockdown restrictions, fitness facilities are getting ready to re-open and welcome back customers. After the pandemic, health has certainly risen to the top of the list of consumers' personal priorities,...

at 03:30
The "Global Molecular Point of Care (mPOC) Devices Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The molecular point of care (mPOC) devices market is poised to grow by $ 816.62 million during 2020-2024 progressing at...



News published on 13 november 2019 at 01:10 and distributed by: